SCHEMBL267931

SCHEMBL267931

COC(=O)c1cc(Cl)ccc1NC(=O)c1cccc(CCl)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.57
KDM4E B2RXH2 4/20 0.57
ALDH1A1 P00352 4/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
NPC1 O15118 2/20 0.57
RAB9A P51151 2/20 0.57
AKR1C4 P17516 1/20 0.54
AKR1C3 P42330 1/20 0.54
AKR1C2 P52895 1/20 0.54
AKR1C1 Q04828 1/20 0.54
SERPINE1 P05121 2/20 0.52
MAPT P10636 6/20 0.51
TDP1 Q9NUW8 1/20 0.51
POLB P06746 2/20 0.48
GAA P10253 1/20 0.48
GFER P55789 1/20 0.48
THRB P10828 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL268374 0.89 ALDH1A1 (0.55) HPGDKDM4EALDH1A1SMN1; SMN2NPC1
SCHEMBL266632 0.87 SMN1; SMN2 (0.54) HPGDKDM4EALDH1A1SMN1; SMN2NPC1
SCHEMBL266398 0.87 AKR1C2 (0.54) HPGDKDM4EALDH1A1SMN1; SMN2NPC1
SCHEMBL269119 0.86 F10 (0.55) HPGDKDM4EALDH1A1SMN1; SMN2NPC1
SCHEMBL418492 0.84 AKR1C4 (0.57) HPGDKDM4EALDH1A1SMN1; SMN2NPC1
SCHEMBL266810 0.83 KDM4E (0.54) HPGDKDM4EALDH1A1SMN1; SMN2NPC1
SCHEMBL265744 0.83 KDM4E (0.53) HPGDKDM4EALDH1A1SMN1; SMN2NPC1
SCHEMBL265743 0.83 KDM4E (0.50) HPGDKDM4EALDH1A1SMN1; SMN2NPC1
SCHEMBL418984 0.83 GRIK1 (0.64) HPGDKDM4EALDH1A1NPC1RAB9A
SCHEMBL420185 0.82 SERPINE1 (0.77) HPGDKDM4EALDH1A1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 HPGD 2509/4885KDM4E 4468/4885ALDH1A1 3022/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 HPGD 2407/4885KDM4E 4535/4885ALDH1A1 2872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.